Molecule Information
General Information of the Molecule (ID: Mol02187)
| Name |
HOX transcript antisense RNA (HOTAIR)
,Mus musculus
|
||||
|---|---|---|---|---|---|
| Synonyms |
Hotair
Click to Show/Hide
|
||||
| Molecule Type |
LncRNA
|
||||
| Gene Name |
Hotair
|
||||
| Gene ID | |||||
| Location |
chr15:102,852,494-102,856,165[-]
|
||||
| Ensembl ID | |||||
| Click to Show/Hide the Complete Species Lineage | |||||
Type(s) of Resistant Mechanism of This Molecule
Drug Resistance Data Categorized by Drug
Approved Drug(s)
2 drug(s) in total
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Disease Class: Chronic obstructive pulmonary disease [ICD-11: CA22.0] | [1] | |||
| Resistant Disease | Chronic obstructive pulmonary disease [ICD-11: CA22.0] | |||
| Resistant Drug | Andrographolide | |||
| Molecule Alteration | Up-regulation | Expression |
||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| In Vitro Model | SV40 cells | N.A. | N.A. | N.A. |
| In Vivo Model | Male BALB/c mice moddel | Mus musculus | ||
| Mechanism Description | Andrographolide antagonizes the cigarette smoke-induced epithelial-mesenchymal transition and pulmonary dysfunction through anti-inflammatory inhibiting HOTAIR. | |||
| Disease Class: Pulmonary dysfunction [ICD-11:BB01.1] | [1] | |||
| Resistant Disease | Pulmonary dysfunction [ICD-11:BB01.1] | |||
| Resistant Drug | Andrographolide | |||
| Molecule Alteration | Up-regulation | Expression |
||
| Experimental Note | Discovered Using In-vivo Testing Model | |||
| In Vitro Model | HBECs | Bronchus | Homo sapiens (Human) | CVCL_0287 |
| In Vivo Model | Male BALB/c mice CS-exposed model | Mus musculus | ||
| Experiment for Drug Resistance |
Annexin V-PI Apoptosis detection; Flow cytometry assay | |||
| Mechanism Description | Andrographolide antagonizes the cigarette smoke-induced epithelial-mesenchymal transition and pulmonary dysfunction through anti-inflammatory inhibiting HOTAIR. | |||
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Disease Class: Silicosis [ICD-11: CA60.0Z] | [1] | |||
| Resistant Disease | Silicosis [ICD-11: CA60.0Z] | |||
| Resistant Drug | Silicon dioxide | |||
| Molecule Alteration | Up-regulation | Interaction |
||
| Experimental Note | Discovered Using In-vivo Testing Model | |||
| In Vitro Model | A549 cells | Lung | Homo sapiens (Human) | CVCL_0023 |
| MRC-5 cells | Lung | Homo sapiens (Human) | CVCL_0440 | |
| NIH/3T3 cells | Whole embryo | Mus musculus (Mouse) | CVCL_0594 | |
| HBE cells | Bronchus | Homo sapiens (Human) | CVCL_0287 | |
| In Vivo Model | Silica-Induced lung Fibrosis mouse model; Lung Fibrosis MiR-326 overexpression mouse model | Mus musculus | ||
| Experiment for Molecule Alteration |
Western bloting analysis; Immunofluorescence assay; Knockdown assay | |||
| Experiment for Drug Resistance |
Dual luciferase reporter assays | |||
| Mechanism Description | miR-326 Inhibits Inflammation and Promotes Autophagy in Silica-Induced Pulmonary Fibrosis through Targeting TNFSF14 and PTBP1. | |||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Yu.
